Skyepharma has announced agreements with Sanofi and Mundipharma that will transfer Mexican, Central American, and South American development, licensing and marketing rights for the Flutiform fluticasone/formoterol MDI to Mundipharma. Sanofi will continue to manufacture Flutiform at its Holmes Chapel, UK facility.
Sanofi licensed those rights from Skyepharma in 2011 and has since gotten approval to market Flutiform in Argentina and Colombia. Mundipharma already markets Flutiform in 29 countries.
Skyepharma CEO Peter Grant commented, “Mundipharma has made very good progress with Flutiform in markets around the world and we welcome the opportunity to further extend our partnership with its international network. Mundipharma is in an excellent position to leverage its substantial experience with Flutiform and to bring this important new treatment option to patients in Mexico, Central and South America.”
President of Mundipharma Asia Pacific, Latin America, Middle East and North Africa, Raman Singh commented, “Asthma has a significant impact on people’s quality of life by affecting the most essential function: the ability to breathe. We at Mundipharma have been focused on developing new and innovative asthma treatment options, and this partnership will enable us to leverage our growing success with Flutiform in the Latin American region. In the many markets where we have launched Flutiform, we have found that it offers a valuable treatment option for patients whose asthma symptoms are not adequately controlled and we believe this will also be the case in Mexico, Central and South America.”
Read the Skyepharma press release.
